Elena Chiorean, MD
Hematology & Oncology · Seattle, WANPI 1891750808
Payments from drug & device makers
Across 429 payments — averaging $12,432 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.3M
- Mirati Therapeutics, Inc.$508K
- E.r. Squibb & Sons, L.L.C.$462K
- Genentech, Inc.$402K
- Stemline Therapeutics Inc.$265K
- Incyte Corporation$254K
- plus $1.1M from 24 others
Across 5 payments — averaging $1134.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$5K
- F. Hoffmann-la Roche AG$778
What the payments were for
- Consulting fees$93,23477%
- Speaking & faculty fees$11,1089%
- Travel & lodging$12,55410%
- Food & beverage$2,7542%
- Education$8391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 55 | $2,340,295 |
| Mirati Therapeutics, Inc. | 31 | $507,663 |
| E.r. Squibb & Sons, L.L.C. | 28 | $461,888 |
| Genentech, Inc. | 95 | $401,794 |
| Stemline Therapeutics Inc. | 25 | $264,614 |
| Incyte Corporation | 50 | $254,432 |
| Novartis | 6 | $219,297 |
| Clovis Oncology, Inc. | 17 | $196,104 |
| Corcept Therapeutics | 25 | $180,881 |
| Eli Lilly | 1 | $149,916 |
| Boehringer Ingelheim | 2 | $69,575 |
| Bristol Myers Squibb | 5 | $55,080 |
| Janssen Research & Development, LLC | 2 | $46,296 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $45,858 |
| Sanofi US Services Inc. | 1 | $36,276 |
| AbbVie | 1 | $18,976 |
| Regeneron | 27 | $16,819 |
| Ipsen Biopharmaceuticals, Inc | 17 | $13,750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $10,168 |
| Array Biopharma Inc | 3 | $9,135 |
| AstraZeneca | 5 | $8,815 |
| Pfizer | 8 | $8,318 |
| Swedish Orphan Biovitrum AB | 3 | $7,477 |
| GSK | 2 | $3,200 |
| G1 Therapeutics, Inc. | 4 | $2,816 |
| Bayer | 1 | $2,457 |
| Aadi Bioscience, Inc. | 1 | $900 |
| Exelixis Inc. | 4 | $225 |
| Gilead | 1 | $84 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,333,136 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZarxioFilgrastim-Sndz | 11 | $16,804 |
| Prochlorperazine Maleate | 26 | $606 |
| LoperamideLoperamide Hcl | 30 | $501 |
| Ondansetron Hcl | 25 | $474 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.